These advances aim to enhance a precision, or personalized, medicine approach to treating our patients. We embrace novel technologies to develop '-omic' data on IBD subjects, reflecting the genomic, immunological and microbiomal phenomena that lead to the development of Crohn's disease and ulcerative colitis.
Our group uses standard and advanced statistical approaches, including deep learning strategies, to determine the relationship between these data and clinical parameters. We collaborate with many other scientists both at Cedars-Sinai and across the world.
Current Translational Research Studies
- Investigating the role of genetic variation and clinical factors in predicting the need for surgery in both ulcerative colitis and Crohn's disease
- The development of novel statistical approaches for combining clinical and '-omic' data
- Studying the contribution of genetic variation to susceptibility in diverse ethnicities including Ashkenazi Jews, Hispanic, East Asian, and populations
- Investigation of the pharmacogenetics of anti-TNF therapy and thiopurine therapies in IBD
- Studying the pleiotropic effects of IBD variants in other traits including immune-mediated, neurological and metabolic diseases
- Epidemiological studies of the extra-intestinal manifestations of IBD and the role of mucosal inflammation in the spondyloarthropathies
- Gene-environmental interaction with a particular emphasis on smoking and host-microbial interactions
Contact us if you have questions, or wish to learn more about the IBIRI.
Inflammatory Bowel & Immunobiology Research Institute
8700 Beverly Blvd.
Davis Building, Suite D4063
Los Angeles CA 90048